Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02030665
Other study ID # 12-174-3
Secondary ID R01DA012728
Status Completed
Phase N/A
First received
Last updated
Start date February 2013
Est. completion date April 2018

Study information

Verified date June 2019
Source UConn Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Marijuana is the most commonly used illicit drug in the US, but treatment for marijuana dependence is not fully effective. In the current proposal we are exploring the idea that more tailored teaching of coping skills may result in improved outcomes for marijuana-dependence than those seen thus far. Participants will be 275 men and women meeting criteria for marijuana dependence and randomly assigned to 9 sessions of treatment in one of 4 treatment conditions: Standardized MET plus CB (SMET-CB); SMET+ CM (SMET-CB-CM); IATP; or IATP + CM (IATP-CM). Patients in all treatments will engage in ES via cell-phone for two weeks prior to treatment, for a weekly period during treatment, for another week after treatment has ended, and for two weekly periods at months 8 and 14. In the IATP conditions, the information gathered from the pretreatment and during-treatment ES periods will provide data for a functional analysis of patients' drug use and urges to use. It is hypothesized that IATP conditions will yield significantly better coping skills acquisition than SMET-CB conditions, both at posttreatment and at extended follow-ups, and that change in coping skills will predict better outcomes for the IATP conditions


Description:

Marijuana is the most commonly used illicit drug in the US, but treatment for marijuana dependence is not fully effective. The most effective treatments to date have employed motivational enhancement (MET) plus cognitive-behavioral coping skills treatment (CB) and contingency management (CM) for abstinence. This proposal is a competitive renewal of our recently completed study to enhance coping and self-efficacy to improve marijuana outcomes in the long term. In the current proposal we are exploring the idea that more tailored teaching of coping skills may result in improved outcomes for marijuana-dependence than those seen thus far. The Individualized Assessment and Treatment Program (IATP) for marijuana dependent patients will employ experience sampling (ES) to determine the strengths and weaknesses of each patient in drug-use situations so that treatment can be tailored accordingly. Results from a pilot study indicated that IATP for alcohol dependent patients yielded better drinking outcomes at posttreatment than a packaged CB program (PCBT), that IATP patients reported greater use of coping skills than PCBT participants, and that posttreatment reports of coping skills were related to posttreatment drinking. Participants will be 275 men and women meeting criteria for marijuana dependence and randomly assigned to 9 sessions of treatment in one of 4 treatment conditions: Standardized MET plus CB (SMET-CB); SMET+ CM (SMET-CB-CM); IATP; or IATP + CM (IATP-CM). Patients in all treatments will engage in ES via cell-phone for two weeks prior to treatment, for a weekly period during treatment, for another week after treatment has ended, and for two weekly periods at months 8 and 14. In the IATP conditions, the information gathered from the pretreatment and during-treatment ES periods will provide data for a functional analysis of patients' drug use and urges to use. Therapists will use the information to address specific cognitions, affects, and behaviors that are adaptive and maladaptive, and will tailor a specific coping skills program with the patient. During-treatment experience sampling will allow adjustment of the treatment goals and procedures, making the treatment adaptive. In the SMET-CB conditions the experience sampling data will not be used in therapy, but will still provide in-vivo measures of drinking and coping skills. It is hypothesized that IATP conditions will yield significantly better coping skills acquisition than SMET-CB conditions, both at posttreatment and at extended follow-ups, and that change in coping skills will predict better outcomes for the IATP conditions. It is further predicted that the addition of CM to both IATP and SMET-CB will enhance short-term and long-term outcomes. The results will have implications for improved tailoring of treatment to patients' strength and deficits, and for the validity of the training of coping skills for relapse prevention. The data collected will shed light on the ways in which patients in treatment use coping skills in real-time contexts. Finally, the use of repeated ES periods will allow us to determine how treatment impacts thoughts, feelings and behaviors, and how these in turn affect outcome in the long and short term.


Recruitment information / eligibility

Status Completed
Enrollment 198
Est. completion date April 2018
Est. primary completion date April 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- at least 18 yrs old

- meet Diagnostic and Statistical Manual IV (DSM-IV) criteria for Cannabis Dependence

- be willing to accept random assignment to any of the 4 treatment conditions

Exclusion Criteria:

- acute medical/psychiatric problems that require inpatient treatment (e.g., acute psychosis, severe depression, suicide/homicide risk)

- reading ability below the fifth grade level

- lack of reliable transportation

- excessive commuting distance.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Contingency Management
Reinforcement provided contingent upon demonstration of negative drug tests
Individualized Assessment & Treatment
Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
Cognitive-Behavioral Treatment
Standard psychoeducational approach to coping skills training

Locations

Country Name City State
United States University of Connecticut Health Center Farmington Connecticut

Sponsors (2)

Lead Sponsor Collaborator
UConn Health National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Marijuana Use Marijuana use measured in terms of Days of use in every 90-day period every 3 months
Secondary Coping Skills Coping Skills measured using the Coping Skills Survey, administered every 3 months every 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00875836 - Buspirone Treatment for Marijuana Dependence Phase 4
Completed NCT00893269 - The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep Phase 1
Completed NCT00490269 - Ph1 Marinol Interaction Study - Part 2 - 1 Phase 1
Completed NCT02579421 - Hormones and Reduction in Co-users of Marijuana and Nicotine N/A
Terminated NCT01598896 - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Phase 2/Phase 3
Completed NCT00373295 - Effect of Baclofen on Marijuana Withdrawal and Relapse Phase 2
Active, not recruiting NCT01827332 - Effect of Oxytocin on Craving and Therapy Response N/A
Completed NCT01335789 - Effect of Oxytocin on Stress in Marijuana Users N/A
Terminated NCT00438139 - Ph1 Marinol Interaction Study - Part 1 - 1 Phase 1
Completed NCT02955329 - Vaping THC From Electronic Cigarettes Phase 3
Completed NCT02439814 - Pregnenolone and Marijuana Dependence Phase 2
Completed NCT01039415 - Attempts to Stop/Reduce Marijuana Among Dependent Users N/A
Completed NCT01347762 - Nabilone for Cannabis Dependence: A Pilot Study Phase 2/Phase 3
Completed NCT00270803 - The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana N/A
Completed NCT01020019 - Combined Pharmacotherapy for Cannabis Dependency Phase 2/Phase 3
Completed NCT00107588 - Marijuana Treatment Project - 3 N/A
Completed NCT02011516 - Baclofen Effects on Marijuana Dependence Phase 2
Recruiting NCT00598052 - Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy N/A
Completed NCT00374127 - Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper Phase 2
Completed NCT00350649 - Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management Phase 2